Oncogenex Pharma wird ACHIEVE LIFE SCIE.
Ich denke hier fehlt es an substanziellen News und entsprechenden Erfolgsmeldungen... mehr nicht.
Ich klinke mich auch aus dem Thread aus , weil es eigentlich wenig Sinn macht, den Markt hier weiter zu kommentieren. Jeder hat seine Theorie und das ist sein gutes Recht.
Ich bleibe dabei: Cytisine hat zuviel Potential , als das es nicht mal beizeiten seinen eigentlichen bisher völlig unterschätzen Wert ausspielen sollte.
Möge bis dahin jeder handeln , wie er lustig ist.
Allseits gute Trades.
Das allein zeigt schon, wie schnell und rasant es hier mal nach oben gehen kann. Und wenn dann noch Volumen dazukäme, kaum auszudenken..
Das ist aber nur die eine Seite, die andere ist leider wenig schön und am Chart abzulesen: Sinkflug pur...
Zweimal habe ich nachgekauft, heute aber nicht mehr. Irgendwann ist die Fahnenstange eben mal erreicht. Die Dinger sind und bleiben jetzt in meinem Depot und ich hoffe darauf, das es eben irgendwann noch mal nach oben rauscht. Wenn nicht, ist es eben so und dann kann ich das investierte Geld wenigstens als Verlustverrechnung zu 1/3 anrechnen. Der Rest WÄRE dann eben Spielgeldverlust.
Aber soweit sind wir noch lange nicht und wer weiß, was hier evtl. noch positives passiert...
Gruß vom
Advamillionär
Aber
Mit Miniumsätzen wird der Kurs weiter nach Süden geprügelt....
Größter Verlierer im Depot...
Bleibe trotzdem weiter an Bord.
Ich finde es auch echt lächerlich (und auch frustrierend) wie sich der Kurs hier entwickelt hat.
Noch ein wenig weiter nach Süden und wir sind wieder im Pennystock...nicht zu glauben.
Ich glaube aber das viele Leute die Meldung und die damit verbundenen Chancen, nicht wirklich verstanden haben. Erfolgt das klinische Phase-3-Programm (voraussichtlich Mitte 2018) von
Cytisin in den Vereinigten Staaten wird es hier wieder so richtig Richtung "Norden" gehen.
Momentan also eigentlich richtige "Schnäppchenpreise" ...
Deshalb,verkaufen werde ich nicht...ich glaube noch an Cytisin und die damit verbundenen Chancen.....
Nur meine Meinung. Keine Kauf- oder Verkaufsempfehlung.
Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017
Mittwoch, 08.11.2017 11:35 von PR Newswire
PR Newswire
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2017
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2017 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference being held on November 28th and 29th at the New York Palace Hotel in New York City.
Achieve logo (PRNewsfoto/Achieve Life Sciences, Inc.)
The Company's presentation will take place on Tuesday, November 28th at 1:30 PM EST in the Kennedy I room. A live webcast of the presentation can be accessed on the investor page of Achieve's website at ir.achievelifesciences.com. A replay of the webcast will also be archived on Achieve's website following the conference.
About Achieve & Cytisine
Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine. Tobacco use is currently the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide1. It is estimated that 28.6% of all cancer deaths in the U.S. are attributable to cigarette smoking2.
Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative. The CASCAID trial was a 1,310 patient, single-blind, non-inferiority trial comparing cytisine to nicotine replacement therapy (NRT). The CASCAID trial was conceived by Dr. Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand. Both trials were published in the New England Journal of Medicine.
Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011, Geneva: World Health Organization, 2011.
2 Annals of Epidemiology , Volume 25 , Issue 3 , 179 - 182.e1
View original content with multimedia:http://www.prnewswire.com/news-releases/...r-28th-2017-300551558.html
SOURCE Achieve Life Sciences, Inc.
Allen viel Glück
wenn man keine Geduld und kein Vertrauen hat, sollte man hier nicht investiert sein! Das hin und her der User nervt langsam!!
Hoffen wir mal das Beste :-)
Gruß
Ain
Donnerstag, 09.11.2017 22:10 von PR Newswire
PR Newswire
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 9, 2017
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 9, 2017 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced financial results for the third quarter ended September 30, 2017.
Achieve logo (PRNewsfoto/Achieve Life Sciences, Inc.)
Third Quarter 2017 Highlights
Consummated merger with OncoGenex Pharmaceuticals
Investigational New Drug (IND) application accepted by the U.S. Food and Drug Administration (FDA) enabling the commencement of cytisine development in the U.S.
Initiated cytisine's clinical development activities in preparation for pivotal U.S. Phase 3 program
Commenced multi-dose study to evaluate the pharmacokinetic/pharmacodynamic characteristics of cytisine in smokers
Completed enrollment in a study evaluating the effect of food on the bioavailability of cytisine
Entered into a share purchase agreement with Lincoln Park Capital Fund, LLC
"I'm extremely pleased with our progress during the period across both clinical and corporate development fronts. Clearly, joining the NASDAQ Capital Markets platform via our merger with OncoGenex was a major milestone as we advance cytisine, our smoking cessation treatment, toward its pivotal U.S. Phase 3 program which remains on track to initiate in mid-2018," commented Rick Stewart, Chairman and Chief Executive Officer of Achieve.
On August 1, 2017, Achieve announced the closing of its merger with publicly listed OncoGenex Pharmaceuticals. The prevailing entity combined operations and employees from both companies with shareholders of Achieve becoming the majority stockholders of OncoGenex in a 1-for-11 reverse stock split with the trading symbol transitioning from OGXI to ACHV.
On August 10th, the U.S. Food and Drug Administration (FDA) accepted Achieve's Investigational New Drug (IND) application for cytisine which provided the Company authorization to commence clinical development of the smoking cessation treatment in the U.S. Cytisine has been approved and marketed in Central and Eastern Europe for more than 25 years. It is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including approximately 2,100 patients in Phase 3 clinical trials conducted in Europe and New Zealand. Achieve has also collaborated with the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH), which has sponsored and completed a number of the preclinical IND-enabling studies .
In preparation for initiating cytisine's pivotal Phase 3 program in the U.S., the Company announced on August 16th, its Clinical Development Plan which entails two phase 1/2 studies aimed at assisting the design and implementation of the subsequent Phase 3 program. The first study was the evaluation of the effect of food on the bioavailability of cytisine, which has completed and data analysis is expected in Q4 2017. The second study was the evaluation of repeat-dose pharmacokinetic and pharmacodynamic characteristics of cytisine in smokers, which commenced in Q4 2017. Data from this repeat-dose study is expected in the first quarter of 2018.
On September 14, the Company announced that it had entered into a share purchase agreement with Lincoln Park Capital Fund, LLC in which Achieve may sell up to $11.0 million of shares of common stock over a 30 month term subject to certain limitations and conditions set forth in the purchase agreement. Through September 30, 2017, the company offered and sold 408,947 shares of common stock to Lincoln Park resulting in proceeds of $1.2 million net of offering costs. As consideration for entering into the Purchase Agreement, we issued to LPC 123,516 shares of common stock; no cash proceeds were received from the issuance of these shares. Achieve plans to utilize the net proceeds from this offering to advance its product candidate cytisine as well as for general corporate purposes. From October 1, 2017 through November 9, 2017, we offered and sold 464,831 shares of our common stock pursuant to our Purchase Agreement with LPC. These sales resulted in gross proceeds to us of approximately $0.9 million.
Financial Results
As of September 30, 2017, the company's cash and cash equivalents were $8.0 million compared with $15,000 as of December 31, 2016.
Total operating expenses for the three and nine months ended September 30, 2017 were $2.4 million and $2.9 million, respectively, compared to $0.4 million and $1.1 million for the three and nine months ended September 30, 2016, respectively.
Net loss for the three and nine months ended September 30, 2017 was $6.5 million and $6.8 million, respectively, compared to $0.3 million and $0.7 million for the three and nine months ended September 30, 2016, respectively.
As of November 9, 2017 Achieve had 11,947,676 shares outstanding.
About Achieve & Cytisine
Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine. Tobacco use is currently the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide1. It is estimated that 28.6% of all cancer deaths in the U.S. are attributable to cigarette smoking2.
Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative. The CASCAID trial was a 1,310 patient, single-blind, non-inferiority trial comparing cytisine to nicotine replacement therapy (NRT). The CASCAID trial was conceived by Dr. Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand. Both trials were published in the New England Journal of Medicine.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of clinical development of cytisine, the market size for cytisine and the potential benefits of cytisine. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisine may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisine; the risk that cytisine will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including the final Proxy Statement/Prospectus/Information Statement filed pursuant to Rule 424(b)(3) in connection with Achieve's recent merger, and Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
On August 1, 2017, Achieve announced the closing of its merger with publicly listed OncoGenex Pharmaceuticals. The prevailing entity combined operations and employees from both companies with shareholders of Achieve becoming the majority stockholders of OncoGenex in a 1-for-11 reverse stock split with the trading symbol transitioning from OGXI to ACHV.
...
Mehr als Merger und Reverse Split war aber leider nicht. Ab dann ging es nur noch abwärts.
Hier wurde wahrscheinlich nur neues billiges Geld eingesammelt und der Aktionär schaut in die Röhre, wie es bei vielen "Pharma"-Unternehmen weltweit und da besonders in den Staaten ist.
Eibentlich hätte man schon hellhörig werden müssen, als man da dieses über 40 Jahre schon existierende Tabex als Heilsbringer avisiert wurde ...
Optionen
| Boardmail an "bozkurt7" |
Wertpapier: Achieve Life Sciences I |
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Achieve Life Sciences I |
Alle anderen sollten Geduld bewahren. schaut euch inotek an, dort war der Kurs auch im Keller und plötzlich... Ich bin leider mit einer Verdreifachung raus, war aber völlig i.O.
Hier wird es ähnlich laufen wenn nicht sogar besser, egal wie das Jahr endet.
Ich glaube wir sehen hier eine Bodenbildung. Es ist nur eine Frage der Zeit...